Mr. Joshua Brumm has been the Chief Executive Officer and the Director of the company since 2025. Prior to this, Mr. Brumm served as a General Partner at Forbion from 2024 to 2025. Previously, he served as the Chief Executive Officer, the President and a Director at Dyne Therapeutics, Inc. He also served as the Chief Operating Officer and the Chief Financial Officer at Kaleido Biosciences, Inc from 2018 to 2019. He served as the Chief Operating Officer and the Chief Financial Officer at Versartis Inc from 2012 to 2013. Mr. Brumm served as a Executive Vice President of Finance and a Principal Financial Officer at Pharmacyclics, LLC and held multiple senior leadership titles at ZELTIQ Aesthetics Inc. He also served as a Director of Finance at Proteolix Inc and held investment banking titles at Citigroup Global Markets Inc and Morgan Stanley.

Mr. Richard Scalzo has been the Chief Financial Officer of the company since 2025. Prior to this, Mr. Scalzo served as a Senior Vice President, Head of Finance and Administration at Dyne Therapeutics Inc from 2022 to 2025. Previously, he served as a Vice President, Accounting and Administration and Treasurer at Dyne Therapeutics, Inc from 2020 to 2022, and as a Corporate Controller at Dyne Therapeutics Inc from 2019 to 2020. Mr. Scalzo also served as a Corporate Controller at Kaleido Biosciences Inc from 2018 to 2019, at X4 Pharmaceuticals, Inc from 2016 to 2018, and at Ocata Therapeutics Inc from 2014 to 2016.

Mr. Jonathan McNeill has been the Chief Operating Officer and the President of the company since 2025. Prior to this, Dr. McNeill served as a Partner at Forbion from January 2025 to March 2025. Previously, he served as the Chief Business Officer at Dyne Therapeutics, Inc from 2023 to 2024, as a Senior Vice President, Business Development at Dyne Therapeutics Inc from 2021 to 2023, and as a Vice President, Business Development at Dyne Therapeutics Inc from 2019 to 2021. He also served as an Associate Director, Business Development at Editas Medicine Inc from 2015 to 2019. Earlier, he served as a Consultant at Boston Consulting Group from 2014 to 2015.

Ms. Ellie Im has been the Chief Medical Officer of the company since 2025. Prior to this, Ms. Im served as a Senior Vice President of Clinical Development, Oncology at Centessa Pharmaceuticals PLC from 2023 to 2025. Previously, she served as a Senior Vice President, Clinical Development and Operations at Mersana Therapeutics Inc from 2023 to 2023, as a Senior Vice President, Head of Clinical Development at Mersana Therapeutics Inc from 2022 to 2023, and as a Vice President, Clinical Development at Mersana Therapeutics Inc from 2021 to 2022. She also served as a Clinical Development Lead and a Senior Medical Director at Tesaro Inc until 2021. Earlier, she served as a Medical Director, Oncology Clinical Development at Merck & Co.

Dr. Jan Pinkas has been the Chief Scientific Officer of the company since July 2025. Previously, he was the Chief Scientific Officer at Pyxis Oncology. Prior to this, he served as Senior Vice President of Translational Sciences at Magenta Therapeutics. Prior to that, he served as Vice President of Translational Research and Development at ImmunoGen. Earlier, Mr. Pinkas worked at Amgen and Genzyme Corporation.